Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World

Acta Tropica

Volumn 118, Issue 2, 2011, Pages 87-96

  Oliveira, Luiz F ^a   Schubach, Armando O ^a   Martins, Maria M ^b   Passos, Sônia L ^a   Oliveira, Raquel V ^a   Marzochi, Mauro C ^a   Andrade, Carlos A ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b Brazil   (Brazil)

Author keywords

Antiprotozoal agents adverse effects; Systematic review, Cutaneous leishmaniasis treatment

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PENTAMIDINE ISETHIONATE; STIBOGLUCONATE SODIUM;

DATABASE; ENZYME ACTIVITY; PROTOZOAN;

ABDOMINAL PAIN; ACUTE KIDNEY TUBULE NECROSIS; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BALANCE DISORDER; BEHAVIOR CHANGE; BITTER TASTE; BLEEDING; CARDIOPULMONARY INSUFFICIENCY; CHILD; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECG ABNORMALITY; EDEMA; ELECTROCARDIOGRAPHY; EOSINOPHILIA; ERYTHEMA; FAINTNESS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART BUNDLE BRANCH BLOCK; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HERPES ZOSTER; HUMAN; HYPERAMYLASEMIA; HYPOGLYCEMIA; HYPOTENSION; INFANT; INJECTION SITE ABSCESS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LABORATORY TEST; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MOTION SICKNESS; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PAIN; PANCREATITIS; PANNICULITIS; PHLEBITIS; PRESCHOOL CHILD; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESPIRATORY FUNCTION; REVIEW; RHABDOMYOLYSIS; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; SKIN MANIFESTATION; ST SEGMENT; SYSTEMATIC REVIEW; T WAVE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TOXIC HEPATITIS; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URTICARIA; VOMITING;

AMPHOTERICIN B; ANTIMONY; ANTIPROTOZOAL AGENTS; DRUG TOXICITY; HUMANS; INCIDENCE; LEISHMANIASIS, CUTANEOUS; PENTAMIDINE;

EID: 79955481379     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.02.007     Document Type: Review

References (90)

1. Andersen E.M., Cruz-Saldarriaga M., Llanos-Cuentas A., Luz-Cjuno M., Echevarria J., Miranda-Verastegui C., Colina O., Berman J.D. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 2005, 72:133-137.
2. Arana B.A., Navin T.R., Arana F.E., Berman J.D., Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin. Infect. Dis. 1994, 18:381-384.
3. Arevalo I., Tulliano G., Quispe A., Spaeth G., Matlashewski G., Llanos-Cuentas A., Pollack H. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin. Infect. Dis. 2007, 44:1549.
4. Armijos R.X., Weigel M.M., Calvopiña M., Mancheno M., Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 2004, 91:153-160.
5. Ballou W.R., McClain J.B., Gordon D.M., Shanks G.D., Andujar J., Berman J.D., Chulay J.D. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987, 2:13-16.
6. Barrios L.A., Costa J.M., Netto E.M., Vexenat C.O., Cuba C.C., Marsden P.D. Intralesional glucantime in Leishmania braziliensis braziliensis infections. Trans. R. Soc. Trop. Med. Hyg. 1986, 80:173-174.
7. Bennett J.E. Antimicrobial: antifungal agents. Goodman and Gilman's the Pharmacological Basis of Therapeutics 2006, 1225-1242. The McGraw-Hill Companies, New York, (Chapter 48). 11th ed. L.S. Goodman, A. Gilman, L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
8. Berman J.D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 1988, 10:560-586.
9. Berman J.J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin. Drug Metab. Toxicol. 2008, 4:1209-1216.
10. Blum J.A., Hatz C.F. Treatment of cutaneous leishmaniasis in travelers 2009. J. Travel Med. 2009, 16:123-131.
11. Blum J., Desjeux P., Schwartz E., Beck B., Hatz C. Treatment of cutaneous leishmaniasis among travelers. JAC 2004, 53:158-166.
12. Brasil Manual de Vigilância da Leishmaniose Tegumentar Americana 2010, Ministério da Saúde, Brasília (DF). 3rd ed.
13. Cavelier C., Foussereau J. Contact allergy to metals and their salts. 3. Others metals. Derm. Beruf. Umwelt. 1995, 43:202-209.
14. Chulay J.D., Oster C.N., McGreevy P.B., Hendricks L.D., Kreutzer R.D. American cutaneous leishmaniasis: presentation and problems of patient management. Rev. Soc. Bras. Med. Trop. 1988, 21:165-172.
15. Convit J., Castellanos P.L., Rondon A., Pinardi M.E., Ulrich M., Castes M., Bloom B., Garcia L. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987, 21:401-405.
16. Correia D., Macêdo V.O., Carvalho E.M., Barral A., Magalhães A.V., de Abreu M.V., Orge M.L., Marsden P. Estudo comparativo entre antimoniato de meglumina, isotianato de pentamidina e sulfato de aminosidina, no tratamento de lesões cutâneas primárias causadas por Leishmania (Viannia) braziliensis. Rev. Soc. Bras. Med. Trop. 1996, 29:447-453.
17. Costa J.M., Garcia A.M., Rêbelo J.M., Guimarães K.M., Guimarães R.M., Nunes P.M. Óbito durante tratamento da leishmaniose tegumentar americana com stibogluconato de sódio bp 88® (shandong xinhua). Rev. Soc. Bras. Med. Trop. 2003, 36:295-298.
18. David C.V., Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol. Ther. 2009, 22:491-502.
19. De Paula C.D.R., Sampaio J.H.D., Cardoso D.R., Sampaio R.N.R. Estudo comparativo da eficácia de isotionato de pentamidina administrada em três doses durante uma semana e de N-metil-glucamina 20mgSbV/kg/dia durante 20 dias para o tratamento da forma cutânea da leishmaniose tegumentar americana. Rev. Soc. Bras. Med. Trop. 2003, 36:365-371.
20. Deeks J.J., Higgins J.P.T., Altman D.G. Including Adverse effects. Cochrane Handbook for Systematic Reviews of Interventions 2006, John Wiley & Sons, Ltd., Chichester, UK, (4.2.6 [updated September 2006]; Appendix 6b. The Cochrane Library, Issue 4, 2006). J.P.T. Higgins, S. Green (Eds.).
21. Delobel P., Pradinaud R. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J. Antimicrob. Chemother. 2003, 51:1319-1320.
22. Deps P.D., Viana M.C., Falqueto A., Dietze R. Avaliaçäo comparativa da eficácia e toxicidade do antimoniato de N-metil-glucamina e do estibogluconato de Sódio BP88© no tratamento da leishmaniose cutânea localizada. Rev. Soc. Bras. Med. Trop. 2000, 33:535-543.
23. Dimier-David L., Valda L., Inofuentes A., Mallea F., David C., Dedet J.P. Traitement de la lésion cutanée de la leishmaniose à Leishmania braziliensis: échec de l'isethionate de pentamidine. Med. Mal. Infect. 1992, 22:1183-1186.
24. FDA, 1994. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A (ICH E2A). (cited 1994 Oct 27). http://www.ich.org/cache/compo/276-254-1.html.
25. FDA, 1996. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice (GCP) E6 (R1) Version 10. (cited June 1996). http://www.ich.org/LOB/media/MEDIA482.pdf.
26. Gadelha A.R., Oliveira W.C., Assunção I.J., Dourado H.V. Tratamento da leishmaniose tegumentar americana com injeções intralesionais de N-metil-glucamina. An. Bras. Dermatol. 1990, 65:201-203.
27. Gasser R.A., Magill A.J., Oster C.N., Franke E.D., Grögl M., Berman J.D. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin. Infect. Dis. 1994, 18:83-90.
28. Gonzáles U., Pinart M., Reginfo-Pardo M., Macaya A., Alvar J., Tweed J.A. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst. Rev. 2009, 15. CD004834.
29. Henderson A., Jolliffe D. Cardiac effects of sodium stibogluconate. Br. J. Clin. Pharmacol. 1985, 19:73-77.
30. Hepburn N.C., Tidman M.J., Hunter J.A. Cutaneous leishmaniasis in British troops from Belize. Br. J. Dermatol. 1993, 128:63-68.
31. Hepburn N.C. Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:691.
32. Hepburn N.C., Tidman M.J., Hunter J.A. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1994, 88:700-703.
33. Hepburn N.C., Siddique I., Howie A.F., Beckett G.J., Hayes P.C. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1994, 88:453-455.
34. Hepburn N.C., Nolan J., Fenn L., Herd R.M., Neilson J.M., Sutherland G.R., Fox K.A. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. QJM 1994, 87:465-472.
35. Herwaldt B.L. Leishmaniasis. Lancet 1999, 354:1191-1199.
36. Herwaldt B.L., Berman J.D. Recommendation for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 1992, 46:296-306.
37. Jones T.C., Johnson W.D., Barretto A.C., Lago E., Badaro R., Cerf B., Reed S.G., Netto E.M., Tada M.S., Franca T.F., et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J. Infect. Dis. 1987, 156:73-83.
38. Kane-Gill S., Rea R.S., Verrico M.M., Weber R.J. Adverse-drug- event rates for high-cost and high-use drugs in the intensive care unit. Am. J. Health Syst. Pharm. 2006, 63:1876-1881.
39. Koerber W.A., Koehn M.C., Jacobs P.H., Russell B.J. Treatment of cutaneous leishmaniasis with antimony sodium gluconate. Arch. Dermatol. 1978, 114:1226.
40. Kopke L.F.F., Vale E.C.S., Araújo M.G., Magalhães P.A., Furtado T. Tratamento da leishmaniose tegumentar americana pelo antimoniato de N-metil-glucamina: estudo duplo-cego com doses de 14mg/Kg/dia e 28mg/Kg/dia de antimoniato. An. Bras. Dermatol. 1991, 66:87-94.
41. Kopke L.F.F., Café M.E.M., Neves L.B., Scherrer M.A.R., Machado-Pinto J., Souza M.S.L.A., et al. Morte após uso de antimonial pentavalente em leishmaniose tegumentar americana. An. Bras. Dermatol. 1993, 68:259-261.
42. Krolewiecki A.J., Romero H.D., Cajal S.P., Abraham D., Mimori T., Matsumoto T., Juarez M., Taranto N.J. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am. J. Trop. Med. Hyg. 2007, 77:640-646.
43. Lai A., Fat E.J., Vrede M.A., Soetosenojo R.M., Lai A., Fat R.F. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int. J. Dermatol. 2002, 41:796-800.
44. Lainson R. The American leishmaniases: some observations on their ecology and epidemiology. Trans. R. Soc. Trop. Med. Hyg. 1983, 77:569-596.
45. Lawn S.D., Armstrong M., Chilton D., Whitty C.J. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:264-269.
46. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 2009, 151:W65-W94.
47. Lima E.B., Porto C., Motta J.O.C., Sampaio R.N.R. Tratamento da leishmaniose tegumentar americana. An. Bras. Dermatol. 2007, 82:111-124.
48. Loke, Y.K., Price, D., Herxheimer, A., 2007. Systematic reviews of adverse effects: framework for a structural approach, BMC Med. Res. Methodol. 7, 32. (accessed April 23, 2008). http://www.biomedcenter.com/1471-2288/7/32.
49. Martinez S., Marr J.J. Allopurinol in the treatment of American cutaneous leishmaniasis. N. Engl. J. Med. 1992, 12(326(11)):741-744.
50. Martinez S., Gonzalez M., Vernaza M.E. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin. Infect. Dis. 1997, 24(2):165-169.
51. Marzochi M.A.C., Marzochi K.B.F. Tegumentary and visceral leishmaniasis in Brazil: emerging anthropozoonosis and possibilities for their control. Cad. Saude Publica 1994, 10(Suppl. 2):S359-S375.
52. Nacher M., Carme B., Sainte Marie D., Couppié P., Clyti E., Guibert P., Pradinaud R. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. 2001, 95:331-336.
53. Name R.Q., Sampaio J.H.D., Borges K.T., Tauil P.L., Nogueira L.S.C., Sampaio R.N.R. Estudo clínico, epidemiologico e terapêutico de 402 pacientes com leishmaniose tegumentar americana atendidos no Hospital Universitário de Brasília, DF, Brasil. An. Bras. Dermatol. 2005, 80:249-254.
54. Navin T.R., Arana B.A., Arana F.E., Mérida A.M., Castillo A.L., Pozuelos J.L. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am. J. Trop. Med. Hyg. 1990, 42:43-50.
55. Navin T.R., Arana B.A., Arana F.E., Berman J.D., Chajón J.F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 1992, 165:528-534.
56. NIH, 2004. Division of AIDS table for grading the severity of adults and pediatric adverse events: December 2004. (accessed May 25, 2009). http://www.ucdmc.ucdavis.edu%3fclinicaltrials/documents/DAIDS_AE_gradingTable_FinalDec2004.pdf.
57. Oliveira-Neto M.P., Schubach A.O., Mattos M., Gonçalves-Costa S.C., Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 1997, 57:651-655.
58. Oliveira-Neto M.P., Schubach A.O., Mattos M., Gonçalves-Costa S.C., Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5mg/kg/day) and high dosage (20mg/kg/day) antimony regimens. Pathol. Biol. (Paris) 1997, 45:496-499.
59. Oliveira-Neto M.P., Schubach A., Mattos M., da Costa S.C., Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil-an area of Leishmania (V.) braziliensis transmission. Int. J. Dermatol. 1997, 36:463-468.
60. Oliveira-Neto M.P., Mattos M., Cuzzi-Maya T., Pirmez C. Paniculite eosinofílica localizada em conseqüência de injeções intramusculares de composto de antimônio pentavalente para o tratamento de leishmaniasis tegumentar americana. An. Bras. Dermatol. 2004, 79:463-469.
61. Oliveira-Neto Manoel Paes de, Mattos Marise da Silva An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable. Rev. Soc. Bras. Med. Trop. 2006, 39:323-326.
62. Oster C.N., Chulay J.D., Hendricks L.D., Pamplin C.L., Ballou W.R., Berman J.D., Takafuji E.T., Tramont E.C., Canfield C.J. American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. Am. J. Trop. Med. Hyg. 1985, 34:856-860.
63. Palacios R., Osorio L.E., Grajalew L.F., Ochoa M.T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg. 2001, 64:187-193.
64. Passos V.M., Barreto S.M., Romanha A.J., Krettli A.U., Volpini A.C., Gontijo C.M., Falcão A.L., Lima-Costa M.F. Leishmaniose tegumentar na região metropolitana de Belo Horizonte: aspectos clínicos, laboratoriais, terapêuticos e evolutivos (1989-1995). Rev. Soc. Bras. Med. Trop. 2001, 34:5-12.
65. Ribeiro A.L., Drummond J.B., Volpini A.C., Andrade A.C., Passos V.M. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz. J. Med. Biol. Res. 1999, 32:297-301.
66. Robledo S.M., Puerta J.A., Muñoz D.L., Guardo M., Velez I.D. Eficacia y tolerancia de la pentamidina en el tratamiento de la leishmaniasis cutánea producida por Leishmania (V.) panamensis en Colombia. Biomedica 2006, 26(Suppl. 1):188-193.
67. Rodrigues M.L., Costa R.S., Souza C.S., Foss N.T., Roselino A.M. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev. Inst. Med. Trop. Sao Paulo 1999, 41:33-37.
68. Romero G.A.S., Hueb M., D'Oliveira A., Schubach A. Simpósio sobre Tratamento das Leishmanioses. Rev. Soc. Bras. Med. Trop. 2001, 34:58-68.
69. Romero G.A.S., Guerra M.V.F., Paes M.G., Macêdo V.O. Comparison of Cutaneous Leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V) guyanensis in Brazil: Therapeutics response to Meglumine Antimoniate. Am. J. Trop. Med. Hyg. 2001, 65:456-465.
70. Romero G.A., Flores M.R.M., Noronha E.F., Macêdo V.O. High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls. Mem. Inst. Oswaldo Cruz 2003, 98:145-149.
71. Roussel M., Nacher M., Frémont G., Rotureau B., Clyti E., Sainte-Marie D., Carme B., Pradinaud R., Couppié P. Comparison between one and two injections of pentamidine isethionate, at 7mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. 2006, 100:307-314.
72. Sáenz R.E., Paz H.M., Johnson C.M., Narváez E., Vásquez A.M. Evaluacion de la efectividad y toxicidad del pentostam y del glucantime em el tratamiento de la leishmaniasis cutânea. Rev. Méd. Panamá 1987, 12:148-157.
73. Sáenz R.E., Paz H., Berman J.D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Med. 1990, 89:147-155.
74. Saldanha A.C.R., Romero G.A.S., Merchan-Hamann E., Magalhães A.V., Macedo V.O. Estudo comparativo entre estibogluconato de sódio BP88® e antimoniato de meglumina no tratamento da leishmaniose cutânea: eficácia e segurança. Rev. Soc. Bras. Med. Trop. 1999, 32:383-387.
75. Saldanha A.C.R., Romero G.A.S., Guerra C., Merchan-Hamann E., Macedo V.O. Estudo comparativo entre estibogluconato de sódio BP 88® e antimoniato de meglumina no tratamento da leishmaniose cutânea: toxidade bioquímica e cardíaca. Rev. Soc. Bras. Med. Trop. 2000, 33:383-388.
76. Scope A., Trau H., Anders G., Barzilai A., Confino Y., Schwartz E. Experience with New World cutaneous leishmaniasis in travelers. J. Am. Acad. Dermatol. 2003, 49:672-678.
77. Seaton R.A., Morrison J., Man I., Watson J., Nathwani D. Out-patient parenteral antimicrobial therapy-a viable option for the management of cutaneous leishmaniasis. QJM 1999, 92:659-667.
78. Solomon M., Baum S., Barzilai A., Scope A., Trau H., Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J. Am. Acad. Dermatol. 2007, 56(4):612-616.
79. Soto J., Buffet P., Grogl M., Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am. J. Trop. Med. Hyg. 1994, 50:107-111.
80. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., Fischer C., Voss A., Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 2001, 33:E57-E61.
81. Soto J., Valda-Rodriquez L., Toledo J., Vera-Navarro L., Luz M., Monasterios-Torrico H., Vega J., Berman J. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 2004, 71:577-581.
82. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 2004, 38:1266-1272.
83. Soto-Mancipe J., Grogl M., Berman J.D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis. 1993, 16:417-425.
84. Talhari S., Sardinha J.C.G., Schettini A.P.M., Arias J., Naiff R.D. Tratamento da leishmaniose tegumentar americana: resultados preliminares com a pentamidina. An. Bras. Dermatol. 1985, 60:361-364.
85. Tuon F.F., Amato V.S., Graf M.S., Siqueira A.M., Nicodemo A.C., Amato Neto V. Treatment of New World cutaneous leishmaniasis-a systematic review with a meta-analysis. Int. J. Dermatol. 2008, 47:109-124.
86. Velez I., Agudelo S., Hendrickx E., Puerta J., Grogl M., Modabber F., Berman J. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med. 1997, 126:232-236.
87. WHO, 2007. Report of the Consultative Meeting on Cutaneous Leishmaniasis. Geneva.
88. Wortmann G.W., Aronson N.E., Byrd J.C., Grever M.R., Oster C.N. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin. Infect. Dis. 1998, 27:509-512.
89. Wortmann G., Miller R.S., Oster C., Jackson J., Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin. Infect. Dis. 2002, 35:261-267.
90. Zlotogorski A., Gilead L., Jonas F., Horev L., Klaus S.N. South American cutaneous leishmaniasis: report of ten cases in Israeli travelers. J. Eur. Acad. Dermatol. Venereol. 1998, 11:32-36.